Investors
Inomagen Therapeutics is a private, preclinical stage biotechnology company developing a non-viral gene therapy that targets the underlying mechanisms of Atrial Fibrillation. To achieve safe and effective gene delivery, the company is developing a novel, patented transcatheter gene delivery system.
Products: Biological (gene) therapy to improve the treatment of atrial fibrillation; and a Proprietary Gene Delivery System
Stage: Preclinical with demonstrated proof-of-concept in over 50 studies using two widely accepted large animal models of AF; advanced into IND-enabling studies with an independent CRO
Billion Dollar Markets: The AF ablation market is $10.2B as of 2022 and is projected to grow to $29B by 2030. Our proprietary gene delivery system can potentially become a platform technology allowing access to additional markets including Ventricular Arrythmias ($12.5B) and Congestive Heart Failure ($17.5B)
Customers: Electrophysiologists, Cardiac Surgeons, and Ventricular Gene therapy companies in need of delivery solutions
Intellectual Property: Exclusive license to 13 issued patents and several pending patents protecting the therapy, delivery, and device. We are continuing to generate additional IP, which is wholly owned by Inomagen
For further information please contact us at: info@inomagen.com